Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)

dc.contributor.authorHarjola, Veli Pekka
dc.contributor.authorMullens, Wilfried
dc.contributor.authorBanaszewski, Marek
dc.contributor.authorBauersachs, Johann
dc.contributor.authorBrunner-La-Rocca, Hans Peter
dc.contributor.authorChioncel, O. Dragomir
dc.contributor.authorCollins, Sean P.
dc.contributor.authorDoehner, Wolfram
dc.contributor.authorFilippatos, Gerasimos S.
dc.contributor.authorFlammer, Andreas J.
dc.contributor.authorFuhrmann, V.
dc.contributor.authorLainščak, Mitja
dc.contributor.authorLassus, Johan P.E.
dc.contributor.authorLegrand, Matthieu M.
dc.contributor.authorMasip, Josep
dc.contributor.authorMüeller, Christian E.
dc.contributor.authorPapp, Zoltán
dc.contributor.authorParissis, John T.
dc.contributor.authorPlatz, Elke
dc.contributor.authorRudiger, Alain
dc.contributor.authorRuschitzka, Frank T.
dc.contributor.authorSchäfer, Andreas
dc.contributor.authorSeferović, Petar M.
dc.contributor.authorSkouri, Hadi N.
dc.contributor.authorYilmaz, Mehmet Birhan
dc.contributor.authorMebazaa, Alexandre
dc.contributor.departmentInternal Medicine
dc.contributor.departmentDivision of Cardiology
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:50:02Z
dc.date.available2025-01-24T11:50:02Z
dc.date.issued2017
dc.description.abstractOrgan injury and impairment are commonly observed in patients with acute heart failure (AHF), and congestion is an essential pathophysiological mechanism of impaired organ function. Congestion is the predominant clinical profile in most patients with AHF; a smaller proportion presents with peripheral hypoperfusion or cardiogenic shock. Hypoperfusion further deteriorates organ function. The injury and dysfunction of target organs (i.e. heart, lungs, kidneys, liver, intestine, brain) in the setting of AHF are associated with increased risk for mortality. Improvement in organ function after decongestive therapies has been associated with a lower risk for post-discharge mortality. Thus, the prevention and correction of organ dysfunction represent a therapeutic target of interest in AHF and should be evaluated in clinical trials. Treatment strategies that specifically prevent, reduce or reverse organ dysfunction remain to be identified and evaluated to determine if such interventions impact mortality, morbidity and patient-centred outcomes. This paper reflects current understanding among experts of the presentation and management of organ impairment in AHF and suggests priorities for future research to advance the field. © 2017 The Authors. European Journal of Heart Failure © 2017 European Society of Cardiology
dc.identifier.doihttps://doi.org/10.1002/ejhf.872
dc.identifier.eid2-s2.0-85020004824
dc.identifier.pmid28560717
dc.identifier.urihttp://hdl.handle.net/10938/30925
dc.language.isoen
dc.publisherJohn Wiley and Sons Ltd
dc.relation.ispartofEuropean Journal of Heart Failure
dc.sourceScopus
dc.subjectHeart failure
dc.subjectMultiple organ failure
dc.subjectVenous congestion
dc.subjectAcute disease
dc.subjectCardiology
dc.subjectDiagnostic imaging
dc.subjectDisease management
dc.subjectEurope
dc.subjectHumans
dc.subjectSocieties, medical
dc.subjectAlkaline phosphatase
dc.subjectAmino terminal pro brain natriuretic peptide
dc.subjectAminotransferase
dc.subjectBilirubin
dc.subjectBiological marker
dc.subjectBlood clotting factor
dc.subjectBumetanide
dc.subjectCreatinine
dc.subjectCystatin c
dc.subjectDiuretic agent
dc.subjectDobutamine
dc.subjectFurosemide
dc.subjectGlyceryl trinitrate
dc.subjectHypertensive factor
dc.subjectInotropic agent
dc.subjectLevosimendan
dc.subjectMilrinone
dc.subjectNeurohormone
dc.subjectNitric acid derivative
dc.subjectNitrogen
dc.subjectNitroprusside sodium
dc.subjectNoradrenalin
dc.subjectOxygen
dc.subjectSerelaxin
dc.subjectTorasemide
dc.subjectTroponin
dc.subjectUrea
dc.subjectUrodilatin
dc.subjectVasodilator agent
dc.subjectAcute heart failure
dc.subjectBiochemistry
dc.subjectBrain
dc.subjectCardiovascular function
dc.subjectClinical assessment
dc.subjectEchocardiography
dc.subjectEchography
dc.subjectGlycocalyx
dc.subjectHeart ventricle pressure
dc.subjectHemodynamics
dc.subjectHormone response
dc.subjectHuman
dc.subjectInflammation
dc.subjectIntestine
dc.subjectKidney
dc.subjectLiver
dc.subjectLung
dc.subjectLung edema
dc.subjectNoninvasive ventilation
dc.subjectOrgan injury
dc.subjectOxygen therapy
dc.subjectPathophysiology
dc.subjectPriority journal
dc.subjectReview
dc.subjectThorax radiography
dc.subjectUrea nitrogen blood level
dc.subjectComplication
dc.subjectMedical society
dc.titleOrgan dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)
dc.typeReview

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2017-8878.pdf
Size:
700.8 KB
Format:
Adobe Portable Document Format